Abstract
Hyperplastic plasmacytotic lymph nodes and Peyer's patches of 12 of 25 (48%) BALB/c mice that carried a human IL-6 transgene under the transcriptional control of the histocompatibility H-2LD promoter (BALB/c.IL-6 mice) were found to harbor 15 cell clones that contained in their T(12;15) translocation breakpoint regions illegitimate genetic recombinations between the upstream flank of the immunoglobulin heavy-chain Cμ locus (5′-Cμ) and c-myc(5′-Cμ/c-myc+ clones). Similar 5′-Cμ/c-myc+ clones were also detected in pristane-induced peritoneal granulomata (a significant source of IL-6 in situ) of three of 13 (13%) conventional BALB/c mice, but not in lymphoid tissues of pristane-treated BALB/c mice, nor in any tissue of untreated BALB/c mice. These findings provided strong evidence that IL-6 may be able to promote the growth and/or survival of clones that contained rearrangements between 5′-Cμ and c-myc. Taken in conjunction with our previous observation that 5′-Cμ/c-myc+ clones are the precursors for pristane-induced BALB/c plasmacytomas, the findings further suggested that IL-6 may play a pivotal role in the early stage of plasmacytoma development, by promoting tumor precursor cells. The BALB/c.IL-6 model of plasmacytomagenesis may be superior to the conventional BALA/c model because the putative plasmacytoma precursors appear to be more prevalent and in their development independent of treating the mice with inflammation-inducing plasmacytomagenic agents, such as pristane or silicone polymers.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Kovalchuk AL, Müller JR, Janz S . Deletional remodeling of c-myc-deregulating translocations Oncogene 1997 15: 2369–2377
Suematsu S, Matsusaka T, Matsuda T, Ohno S, Miyazaki J, Yamamura K, Hirano T, Kishimoto T . Generation of plasmacytomas with the chromosomal translocation t(12;15) in interleukin 6 transgenic mice Proc Natl Acad Sci USA 1992 89: 232–235
Müller JR, Potter M, Janz S . Differences in the molecular structure of c-myc-activating recombinations in murine plasmacytomas and precursor cells Proc Natl Acad Sci USA 1994 91: 12066–12070
Müller JR, Jones GM, Janz S, Potter M . Migration of cells with immunoglobulin/c-myc recombinations in lymphoid tissues of mice Blood 1997 89: 291–296
Müller JR, Jones GM, Potter M, Janz S . Detection of immunoglobulin/c-myc recombinations in mice that are resistant to plasmacytoma induction Cancer Res 1996 56: 419–423
Kovalchuk AL, Potter M, Janz S . DNA sequence analysis of the genetic recombination between Igh6 and Myc in an uncommon BALB/c plasmacytoma, TEPC 1194 Immunogenetics 1996 44: 151–156
Ohno S, Hayakawa J, Hashimoto N, Wiener F . Murine plasmacytomas, carrier of the t(12;15) chromosomal translocation, develop from immature/mature B cells not from differentiated plasma cells Carcinogenesis 1999 20: 529–538
Cory S . Activation of cellular oncogenes in hemopoietic cells by chromsome translocation Adv Cancer Res 1986 47: 189–234
Yang JQ, Bauer SR, Mushinski JF, Marcu KB . Chromosome translocations clustered 5′ of the murine c-myc gene qualitatively affect promoter usage: implications for the site of normal c-myc regulation EMBO J 1985 4: 1441–1447
Fahrlander PD, Sumegi J, Yang JQ, Wiener F, Marcu KB, Klein G . Activation of the c-myc oncogene by the immunoglobulin heavy-chain gene enhancer after multiple switch region-mediated chromosome rearrangements in a murine plasmacytoma Proc Natl Acad Sci USA 1985 82: 3746–3750
Adams JM, Harris AW, Pinkert CA, Corcoran LM, Alexander WS, Cory S, Palmiter RD, Brinster RL . The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice Nature 1985 318: 533–538
Dunnick W, Hertz GZ, Scappino L, Gritzmacher C . DNA sequences at immunoglobulin switch region recombination sites Nucleic Acids Res 1993 21: 365–372
Gutierrez MI, Bhatia K, Barriga F, Diez B, Muriel FS, de Andreas ML, Epelman S, Risueno C, Magrath IT . Molecular epidemiology of Burkitt's lymphoma from South America: differences in breakpoint location and Epstein–Barr virus association from tumors in other world regions Blood 1992 79: 3261–3266
Dunnick W, Wilson M, Stavnezer J . Mutations, duplication, and deletion of recombined switch regions suggest a role for DNA replication in the immunoglobulin heavy-chain switch Mol Cell Biol 1989 9: 1850–1856
Radbruch A, Burger C, Klein S, Muller W . Control of immunoglobulin class switch recombination Immunol Rev 1986 89: 69–83
Ohki R, Hirota M, Oishi M, Kiyama R . Conservation and continuity of periodic bent DNA in genomic rearrangements between the c-myc and immunoglobulin heavy chain mu loci Nucleic Acids Res 1998 26: 3026–3033
Cerutti A, Zan H, Schaffer A, Bergsagel L, Harindranath N, Max EE, Casali P . CD40 ligand and appropriate cytokines induce switching to IgG, IgA, and IgE and coordinated germinal center and plasmacytoid phenotypic differentiation in a human monoclonal IgM+IgD+B cell line J Immunol 1998 160: 2145–2157
Kiuchi N, Nakajima K, Ichiba M, Fukada T, Narimatsu M, Mizuno K, Hibi M, Hirano T . STAT3 is required for the gp130-mediated full activation of the c-myc gene J Exp Med 1999 189: 63–73
Hinson RM, Williams JA, Shacter E . Elevated interleukin 6 is induced by prostaglandin E2 in a murine model of inflammation: possible role of cyclooxygenase-2 Proc Natl Acad Sci USA 1996 93: 4885–4890
Shacter E, Arzadon GK, Williams J . Elevation of interleukin-6 in response to a chronic inflammatory stimulus in mice: inhibition by indomethacin Blood 1992 80: 194–202
Potter M, MacCardle RC . Histology of developing plasma cell neoplasia induced by mineral oil in BALB/c mice J Natl Cancer Inst 1964 33: 497–515
Potter M, Wax J, Jones GM . Indomethacin is a potent inhibitor of pristane and plastic disc induced plasmacytomagenesis in a hypersusceptible BALB/c congenic strain Blood 1997 90: 260–269
Byrd LG, McDonald AH, Gold LG, Potter M . Specific pathogen-free BALB/cAn mice are refractory to plasmacytoma induction by pristane J Immunol 1991 147: 3632–3637
Nordan RP, Potter M . A macrophage-derived factor required by plasmacytomas for survival and proliferation in vitro Science 1986 233: 566–569
Degrassi A, Hilbert DM, Rudikoff S, Anderson AO, Potter M, Coon HG . In vitro culture of primary plasmacytomas requires stromal cell feeder layers Proc Natl Acad Sci USA 1993 90: 2060–2064
Vink A, Coulie P, Warnier G, Renauld JC, Stevens M, Donckers D, Van Snick J . Mouse plasmacytoma growth in vivo: enhancement by interleukin 6 (IL-6) and inhibition by antibodies directed against IL-6 or its receptor J Exp Med 1990 172: 997–1000
Lattanzio G, Libert C, Aquilina M, Cappelletti M, Ciliberto G, Musiani P, Poli V . Defective development of pristane-oil-induced plasmacytomas in interleukin-6-deficient BALB/c mice Am J Pathol 1997 151: 689–696
Hilbert DM, Kopf M, Mock BA, Kohler G, Rudikoff S . Interleukin 6 is essential for in vivo development of B lineage neoplasms J Exp Med 1995 182: 243–248
Largaespada DA, Kaehler DA, Mishak H, Weissinger E, Potter M, Mushinski JF, Risser R . A retrovirus that expresses v-abl and c-myc oncogenes rapidly induces plasmacytomas Oncogene 1992 7: 811–819
Weissinger EM, Byrd LG, Henderson DW, Mushinski JF . Overexpression of v-abl uniquely cooperates with c-myc dysregulation in induction of plasma cell tumors, bypassing the need for T-lymphocytic help and overcoming T-lymphocytic interference Int J Cancer 1996 67: 142–147
Hilbert DM, Migone TS, Kopf M, Leonard WJ, Rudikoff S . Distinct tumorigenic potential of abl and raf in B cell neoplasia: abl activates the IL-6 signaling pathway Immunity 1996 5: 81–89
Suematsu S, Matsuda T, Aozasa K, Akira S, Nakano N, Ohno S, Miyazaki J, Yamamura K, Hirano T, Kishimoto T . IgGl plasmacytosis in interleukin 6 transgenic mice Proc Natl Acad Sci USA 1989 86: 7547–7551
Madisen L, Groudine M . Identification of a locus control region in the immunoglobulin heavy-chain locus that deregulates c-myc expression in plasmacytoma and Burkitt's lymphoma cells Genes Dev 1994 8: 2212–2226
Prendergast GC . Mechanisms of apoptosis by c-Myc Oncogene 1999 18: 2967–2987
Acknowledgements
We are grateful to Dr Michael Potter for providing BALB/c.IL-6 mice and numerous insightful discussions throughout the experiments. We acknowledge the staff of our mouse colony, particularly Wendy DuBois, for animal husbandry. We thank Dr Rebecca Liddell for reading the manuscript and making helpful editorial suggestions. We also thank EB Mushinski for performing immunostaining.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kovalchuk, A., Kishimoto, T. & Janz, S. Lymph nodes and Peyer's patches of IL-6 transgenic BALB/c mice harbor T(12;15) translocated plasma cells that contain illegitimate exchanges between the immunoglobulin heavy-chain μ locus and c-myc. Leukemia 14, 1127–1135 (2000). https://doi.org/10.1038/sj.leu.2401767
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2401767
Keywords
This article is cited by
-
Preclinical validation of interleukin 6 as a therapeutic target in multiple myeloma
Immunologic Research (2014)
-
18F-FDG-PET/CT imaging in an IL-6- and MYC-driven mouse model of human multiple myeloma affords objective evaluation of plasma cell tumor progression and therapeutic response to the proteasome inhibitor ixazomib
Blood Cancer Journal (2013)
-
Genetic reporter system for oncogenic Igh–Myc translocations in mice
Oncogene (2010)
-
Gene expression profiling reveals different pathways related to Abl and other genes that cooperate with c-Myc in a model of plasma cell neoplasia
BMC Genomics (2007)
-
Response to 'Amplifying Igh translocations'
Nature Immunology (2005)